Angina Pectoris Market size is estimated to reach $12.9 billion by 2027, growing at a CAGR of 4.8% during the forecast period 2022-2027. Angina pectoris is the medical term for chest pain or discomfort owing to coronary heart disease. It happens when the heart muscle does not acquire as much blood as it requires. Sublingual nitroglycerin has been the backbone of treatment for angina pectoris. Sublingual nitroglycerin can be utilized for acute alleviation of angina and prophylactically prior to actions that may accelerate angina. Myocardial ischemia is one of the more typical causes of chest pain (also termed "chest discomfort") in mature grown-ups. Angina pectoris, or angina in brief, is the term utilized when chest discomfort is thought to be traceable to myocardial ischemia. Ischemic heart disease is one of the most typical cardiovascular ailments in developed nations and angina pectoris is the most typical condition including tissue ischemia in which medications pertaining to vasodilators are utilized. Vasodilator blockers and calcium blockers have easy-to-foretell advantages in angina. Polycythemia vera is a myeloproliferative ailment represented by occasional thromboembolic complexities like ischemic heart disease. A case of polycythemia vera demonstrating angina pectoris without coronary artery stenosis has been recorded.
The increasing predominance of cardiac ailments like coronary heart disease and the surging application of vasodilators for the treatment of heart conditions like heart failure and angina are set to drive the Angina Pectoris Market. The continued R&D efforts in the field of Angina Pectoris, resulting in the introduction of new and efficient medications is set to propel the growth of the Angina Pectoris Industry during the forecast period 2022-2027. This represents the Angina Pectoris Industry Outlook.
Angina Pectoris Market Report Coverage
The “Angina Pectoris Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Angina Pectoris Market.
by Drug Class: Beta Blockers, Calcium Antagonists, Anti-Coagulants, Anti-Platelets, Nitrates, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Others.
by Disease Type: Stable Or Chronic Angina, Unstable Angina, Variant And Microvascular Angina.
by Geography: North America (U.S, Canada and Mexico), Europe (Germany, France, UK, Italy, Spain, Russia and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America) and Rest Of The World (Middle East, Africa).
Key Takeaways
- Geographically, North America (Angina Pectoris market share) is accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027 owing to the increasing predominance of angina pectoris requiring application of sublingual nitroglycerin, big base of pharmaceutical firms, soaring awareness levels, well-entrenched healthcare facilities and agreeable medical reimbursement policies in the North American region.
- Angina Pectoris Market growth is being driven by the rising count of patients being subjected to treatment for Angina Pectoris which may require application of sublingual nitroglycerin and probable approval of novel therapies. However, the side-effects connected with some drug classes is one of the major factors hampering the growth of Angina Pectoris Market.
- Angina Pectoris Market Detailed Analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market will be provided in the Angina Pectoris Market report.
Angina Pectoris Market Segment Analysis - by Drug Class
The Angina Pectoris Market based on drug class can be further segmented into Beta Blockers, Calcium Antagonists, Anti-Coagulants, Anti-Platelets, Nitrates, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Others. The Beta Blockers Segment held the largest Angina Pectoris market share in 2021. This growth is owing to the heightening application of beta blockers as first-line therapy for treatment of Angina Pectoris. Polycythemia vera is a myeloproliferative ailment characterized by infrequent thromboembolic complexities like ischemic heart disease. The surging target population and the increasing count of strategic developments amidst the market players for boosting the commercial accessibility of beta blocker medications are further propelling the growth of the Beta Blockers segment.
Furthermore, the Nitrates segment is estimated to grow with the fastest CAGR of 5.8% during the forecast period 2022-2027 owing to the surging application of nitrates which are peripheral and coronary vasodilators utilized in the management of angina pectoris, heart failure and myocardial infarction.
Angina Pectoris Market Segment Analysis - by Disease Type
The Angina Pectoris Market based on disease type can be further segmented into Stable or Chronic Angina, Unstable Angina, Variant And Microvascular Angina. The Stable or Chronic Angina Segment held the largest Angina Pectoris market share in 2021. This growth is owing to the increasing count of patients with chronic stable angina which is the beginning demonstration of ischemic heart disease in nearly one half of patients. Stable angina (angina pectoris) is a kind of chest pain that occurs when the heart muscle requires more oxygen than normal however, it is not acquiring it at that moment owing to heart disease. Stable angina may be caused when it is cold outside or when exercising and this is further propelling the growth of this segment.
Furthermore, the Unstable Angina segment is estimated to grow with the fastest CAGR of 6.1% during the forecast period 2022-2027 owing to the increasing stress or exertion or at rest.
Angina Pectoris Market Segment Analysis - by Geography
The Angina Pectoris Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and Rest of the World. North America (Angina Pectoris Market) held the largest Angina Pectoris market share with 36% of the overall market in 2021. The growth of this region is owing to the well-entrenched healthcare infrastructure and surging acceptance of therapeutics in the North American region. Polycythemia vera is a rare condition and polycythemia vera is usually connected with an elevated white blood cell count (leukocytosis) and platelet count (thrombocytosis). The existence of key players like Anthera Pharmaceuticals in U.S. is further propelling the growth of the Angina Pectoris Industry, thereby contributing to the Angina Pectoris Industry Outlook, in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR rate over the forecast period 2022-2027. This growth is owing to factors like the extensive market for medications pertaining to Angina Pectoris alongside progress in the field of drug development in the Asia-Pacific region. The increasing predominance of coronary heart disease amidst South Asians in industrialized nations is further fuelling the progress of the Angina Pectoris Market in the Asia-Pacific region.
Angina Pectoris Market Drivers
Surging Applications of Sublingual Nitroglycerin are Projected to Drive the Growth of Angina Pectoris Industry:
The short-acting nitrite sublingual nitroglycerin is the backbone of drug treatment of angina pectoris. It is most beneficial when provided two to three minutes prior to activity that may accelerate an anginal attack. Nitroglycerin Sublingual is a prescription medicine utilized in the treatment or prophylaxis of acute Angina Pectoris. Nitroglycerin Sublingual is accessible under the following distinct brand names: Nitrostat, Nitrolingual Pumpspray, GoNitro, NitroQuick, Glyceryl Trinitrate Sublingual, Sublingual Nitroglycerin. The adult dosage of Nitroglycerin Sublingual for Angina Pectoris (Acute Relief) is 0.3-0.6mg SL every 5 minutes up to 3 times and needs to be utilized at the earliest sign of angina. The surging applications of sublingual nitroglycerin are therefore fuelling the growth of the Angina Pectoris Industry, thereby contributing to the Angina Pectoris Industry Outlook, during the forecast period 2022-2027.
Significance of Myocardial Ischemia is Expected to Boost the Growth of the Angina Pectoris Market:
Angina pectoris is the outcome of myocardial ischemia brought about by an imbalance between myocardial blood supply and oxygen demand. It is a typical displaying symptom (usually, chest pain) amidst patients with coronary artery disease (CAD). Nearly 9.8 million Americans are predicted to endure angina annually, with 500,000 novel cases of angina happening each year. Patients need to be asked regarding the frequency of angina, severity of pain and count of nitroglycerin pills utilized at the time of episodes. Currently, vasodilators are not suggested at the time of the ischemic stage, though certain proof recommends that preload alteration by application of nitroglycerin may be advantageous in some cases. The significance of Myocardial Ischemia is therefore driving the growth of the Angina Pectoris Market during the forecast period 2022-2027.
Angina Pectoris Market Challenges
Limitations of Vasodilators in Treatment of Angina Pectoris are Hampering the Growth of the Angina Pectoris Market:
As a result of its continued action, the oxygen requirements of the heart are comparatively high and it extracts nearly 75% of the accessible oxygen even in the absence of stress. The myocardial oxygen need raises when there is an rise in heart rate, contractility, arterial pressure or ventricular volume. These hemodynamic changes repeatedly happen at the time of physical exercise and sympathetic discharge, which frequently accelerate angina in patients with obstructive coronary artery disease. There are three potential limitations in the application of vasodilators. Systemic vasodilation and arterial pressure decrease can result in a baroreceptor-mediated reflex stimulation of the heart (raised heart rate and inotropy). This boosts oxygen demand, which is unacceptable if the patient also is enduring coronary artery disease. Vasodilators can harm normal baroreceptor-mediated reflex vasoconstriction when a person stands up, which can result in orthostatic hypotension and syncope upon standing. These issues are thus hampering the growth of the Angina Pectoris Market.
Angina Pectoris Industry Outlook
Development of progressive products for superior outcomes, mergers and acquisitions, collaborations, joint ventures, R&D activities and precise marketing are key strategies adopted by players in the Angina Pectoris Market. The top 10 companies in the Angina Pectoris market are:
- Anthera Pharmaceuticals
- Cardium Therapeutics
- Astellas Pharma
- Sanofi S.A.
- Bayer HealthCare
- Cardeus Pharmaceuticals
- CardioVascular BioTherapeutics (CVBT)
- Merck & Co. Inc
- Ark Therapeutics Group plc
- Torrent Pharmaceuticals Limited
Recent Developments
- In July 2022, Astellas Pharma Inc. and Seagen Inc. declared positive topline outcomes from the phase 1b/2 EV-103 clinical trial (also termed as KEYNOTE-869) Cohort K evaluating PADCEV® (enfortumab vedotin-ejfv) in integration with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) as first-line treatment in patients with unresectable locally progressive or metastatic urothelial cancer (la/mUC) who are ineligible to accept cisplatin-based chemotherapy. Merck is recognized as MSD outside the U.S. and Canada. In patients treated with enfortumab vedotin and pembrolizumab, outcomes established a 64.5% confirmed objective response rate (ORR) (95% CI: 52.7 to 75.1) per blinded independent central review (BICR), the primary endpoint of Cohort K.
- In July 2022, Astellas Pharma Inc. declared plans to develop an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center. The novel 154,000-square-foot building at 480 Forbes Boulevard will permit for the co-location of numerous Astellas business units and functions presently situated independently all through the San Francisco area. The novel innovation and research center will involve employees across research, technical operations, medical and development, commercial and appropriate administrative support functions.
- In October 2021, Astellas Pharma started applying sugarcane-derived polyethylene as 50% of its raw material for developing pharmaceutical blister packs. The firm pronounces the move as “the world’s first use” of biomass plastic for drug blister packs. Astellas will begin utilizing the biomass-based plastic blister pack for its “Irribow Tablet 5µg” tablets on the Japanese market, which aim diarrhoea-predominant irritable bowel syndrome. This concludes the Angina Pectoris Industry Outlook.
Relevant Reports:
Report Code: HCR 53444
Report Code: HCR 16954
Report Code: HCR 20420
For more Lifesciences and Healthcare Market reports, please click here
